title: In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.
abstract: BACKGROUND
  Passive transfer of antibodies can be protective in the simian human immunodeficiency virus (SHIV)--rhesus macaque challenge model. The human monoclonal antibody IgG1 b12 neutralizes human immunodeficiency type 1 (HIV-1) in vitro and protects against challenge by SHIV. Our hypothesis is that neutralizing antibodies can only completely inactivate a relatively small number of infectious virus.
  
  
  RESULTS
  We have used GHOST cell assays to quantify individual infectious events with HIV-1SF162 and its SHIV derivatives: the relatively neutralization sensitive SHIV(SF162P4) isolate and the more resistant SHIV(SF162P3). A plot of the number of fluorescent GHOST cells with increasing HIV-1SF162 dose is not linear. It is likely that with high-dose inocula, infection with multiple virus produces additive fluorescence in individual cells. In studies of the neutralization kinetics of IgG1 b12 against these isolates, events during the absorption phase of the assay, as well as the incubation phase, determine the level of neutralization. It is possible that complete inactivation of a virus is limited to the time it is exposed on the cell surface. Assays can be modified so that neutralization of these very low doses of virus can be quantified. A higher concentration of antibody is required to neutralize the same dose of resistant SHIV(SF162P3) than the sensitive SHIV(SF162P4). In the absence of selection during passage, the density of the CCR5 co-receptor on the GHOST cell surface is reduced. Changes in the CD4 : CCR5 density ratio influence neutralization.
  
  
  CONCLUSIONS
  Low concentrations of IgG1 b12 completely inactivate small doses of the neutralization resistant SHIV(SF162P3). Assays need to be modified to quantify this effect. Results from modified assays may predict protection following repeated low-dose shiv challenges in rhesus macaques. It should be possible to induce this level of antibody by vaccination so that modified assays could predict the outcome of human trials.
authors: Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands. davis@bprc.nl
authors: David
authors: D
authors: Davis
authors: Wim
authors: W
authors: Koornstra
authors: Zahra
authors: Z
authors: Fagrouch
authors: Ernst J
authors: EJ
authors: Verschoor
authors: Jonathan L
authors: JL
authors: Heeney
authors: Willy M J M
authors: WM
authors: Bogers
mesh_terms: D065567:Absorption, Physiological; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology*; D002452:Cell Count; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D004306:Dose-Response Relationship, Immunologic; D005434:Flow Cytometry; D005453:Fluorescence; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D016014:Linear Models; D008253:Macaca mulatta / Q000276:immunology* / Q000821:virology; D009500:Neutralization Tests; D019713:Receptors, CCR5 / Q000378:metabolism; D012692:Serial Passage; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D019713:Receptors, CCR5
references: J Med Primatol. 1999 Aug-Oct;28(4-5):164-8
references: 10593481
references: PLoS One. 2011;6(12):e28974
references: 22216149
references: Blood. 1985 Apr;65(4):1002-9
references: 3872139
references: J Med Virol. 2003 Feb;69(2):173-81
references: 12683404
references: Virology. 2004 Jan 5;318(1):267-79
references: 14972553
references: J Med Virol. 2003 Nov;71(3):332-42
references: 12966537
references: Science. 1999 Apr 30;284(5415):816-9
references: 10221916
references: Nature. 2010 Sep 30;467(7315):591-5
references: 20882016
references: Vaccine. 2003 Dec 8;22(1):104-11
references: 14604577
references: AIDS. 2008 Jan 30;22(3):339-48
references: 18195560
references: Virology. 2008 Dec 20;382(2):217-25
references: 18947849
references: Science. 1994 Nov 11;266(5187):1024-7
references: 7973652
references: Curr Mol Med. 2003 May;3(3):209-16
references: 12699358
references: Proc Natl Acad Sci U S A. 1988 Apr;85(8):2815-9
references: 3357892
references: Nature. 2002 Dec 12;420(6916):678-82
references: 12478295
references: Ann Neurol. 1988;23 Suppl:S58-61
references: 3258140
references: Virology. 2006 Aug 15;352(1):216-25
references: 16725169
references: Immunol Lett. 2001 Nov 1;79(1-2):47-55
references: 11595289
references: J Virol. 1999 Mar;73(3):2343-9
references: 9971817
references: Nat Rev Immunol. 2009 Oct;9(10):717-28
references: 19859066
references: Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11518-22
references: 7505441
references: Proc Natl Acad Sci U S A. 1989 Nov;86(21):8575-9
references: 2813413
references: Methods Mol Biol. 2009;525:559-66, xiv
references: 19252837
references: Science. 1998 Jun 19;280(5371):1884-8
references: 9632381
references: Nat Med. 2010 Oct;16(10):1117-9
references: 20890292
references: J Med Virol. 2006 Jul;78(7):864-76
references: 16721864
references: J Med Virol. 2001 Jul;64(3):207-16
references: 11424106
references: J Virol. 2004 Dec;78(23):13232-52
references: 15542675
references: AIDS Res Hum Retroviruses. 2006 Oct;22(10):1022-30
references: 17067273
references: J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):383-7
references: 16280691
references: Clin Infect Dis. 2008 Aug 1;47(3):401-9
references: 18558875
references: J Virol. 2007 Jun;81(12):6402-11
references: 17392364
references: J Virol. 2007 Aug;81(16):8621-33
references: 17537860
references: J Virol. 2003 Jan;77(2):989-98
references: 12502815
references: Nature. 2007 Feb 15;445(7129):732-7
references: 17301785
references: J Virol. 2001 Sep;75(17):8340-7
references: 11483779
references: AIDS Res Hum Retroviruses. 2000 Jul 1;16(10):981-94
references: 10890360
references: J Virol. 1998 Oct;72(10):7840-5
references: 9733820
references: AIDS Rev. 2004 Oct-Dec;6(4):187-98
references: 15700617
references: Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7490-4
references: 7638218
references: Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17477-82
references: 17956985
references: J Virol. 2001 Feb;75(4):1990-5
references: 11160699
references: Sci Transl Med. 2011 May 4;3(81):81ra36
references: 21543722
references: Virology. 2007 May 25;362(1):207-16
references: 17258783
references: J Virol. 2003 Oct;77(19):10348-56
references: 12970419
references: Nature. 2007 Sep 6;449(7158):101-4
references: 17805298
references: J Med Primatol. 2003 Aug;32(4-5):211-7
references: 14498981
references: J Med Primatol. 2008 Dec;37 Suppl 2:13-23
references: 19187427
references: J Virol. 2012 Jun;86(11):6189-96
references: 22457527
references: J Virol. 2010 Jun;84(12):5975-85
references: 20392857
references: J Virol. 1998 Sep;72(9):6988-96
references: 9696790
references: Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9434-8
references: 1409653
references: Adv Exp Med Biol. 1996;397:169-82
references: 8718596
references: Vaccine. 2004 Jan 26;22(5-6):747-54
references: 14741168
references: Nat Med. 2009 Aug;15(8):951-4
references: 19525965
references: AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):243-51
references: 11177407